Logo image
Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?
Journal article   Peer reviewed

Is Management of Central Retinal Artery Occlusion the Next Frontier in Cerebrovascular Diseases?

Kaustubh Limaye, Michael Wall, Sami Uwaydat, Sheharayar Ali, Amir Shaban, Sami Al Kasab and Harold Adams
Journal of stroke and cerebrovascular diseases, Vol.27(10), pp.2781-2791
10/2018
DOI: 10.1016/j.jstrokecerebrovasdis.2018.06.006
PMID: 30060907

View Online

Abstract

Central retinal artery occlusion (CRAO) is a medical emergency that, if not treated, may result in irreversible loss of vision. It continues to be an important cause for acute painless loss of vision. Amaurosis fugax or “transient CRAO” has long been considered an equivalent of transient cerebral ischemic event. Animal models, in addition to data from retrospective and randomized clinical studies, provide valuable insights into the time interval for irreversible retinal ischemia. Subset analyses from 2 large studies of patients with CRAO show benefit from treatment with thrombolysis within 6 hours from symptoms onset. Significant workflow improvements after the intra-arterial therapy trials for acute ischemic stroke have occurred world over in last 5 years. Patients with CRAO are uniquely suited to receive maximum benefits from the changes in workflow for treatment of patient's acute ischemic stroke. Just as in clinical triage of acute ischemic stroke, correct and timely diagnosis of patients with CRAO may help in preventing visual loss. The approach to acute ocular ischemia should mimic that used for acute brain ischemia. Comprehensive stroke centers would be ideal triage centers for these patients in view of availability of multidisciplinary participation from vascular neurology, neuroendovascular surgery, and ophthalmology. Time is Retina!
thrombolysis intra-arterial therapy intravenous central retinal artery occlusion Hyperacute stroke

Details

Logo image